Company Overview and News
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio. One such stock that you may want to consider dropping is Cooper Tire & Rubber Company (CTB - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
BRDCF FBC BRDCY ELLI
Autoliv, Inc. (ALV) reported adjusted earnings of $1.66 per share in first-quarter 2018, missing the Zacks Consensus Estimate of $1.81. However, the bottom line improved from the prior-year quarter’s $1.65.
BRDCF BRDCY CNA ALV BWA
(Reuters) - Goodyear Tire & Rubber Co’s (GT.O) quarterly profit more than halved on Wednesday as demand for its tires were weaker than expected and higher costs of raw materials weighed on its business.
President Donald Trump and Japan’s prime minister Shinzo Abe on Wednesday agreed to start a fresh dialogue and establish a new framework for trade and investment between the two countries. The trade talks are aimed at balancing United States’ trade deficit with Japan. Trump has been critical of Japan in recent times, describing the terms of trade between them as “not fair” because of the huge trade deficit with that country.
BRDCF BLT BHPBF WDC DSCSY RICOY BHP BRDCY 8306 MUFG BBL BHP BHPLF MBFJF MTU NJDCY NNDNF
Tesla, Inc. (TSLA - Free Report) set a target to manufacture 6,000 Model 3 cars each week by the end of June to meet its weekly target of 5,000 Model 3 units by the end of second-quarter 2018, per Bloomberg. The difference includes a margin for error of the product parts. The news was first tracked by Electrek from an email from the company’s CEO to the employees.
BRDCF ABX MS.PRI BRDCY MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA ABX
The Goodyear Tire & Rubber Company (GT - Free Report) announced that it is entering a 50-50 joint venture (JV) with Bridgestone Americas, Inc. (Bridgestone), which is the U.S. subsidiary of Bridgestone Corporation (BRDCY - Free Report) , to form the largest tire-distribution network in the United States. TireHub LLC, the new JV, will offer a complete range of light-truck and passenger-vehicle tires with primary importance on fulfilling the rising demand for larger rim-diameter premium tires.
BRDCF APO.PRB APO.PRA MS.PRE MS.PRF MS.PRG MS.PRA APO VLKAF MS.PRI BRDCY MS.PRK BWA MS VLKAY
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
ELY BRDCF NKE PEP GOLF
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BGX BLK BRDCF SNE BGLF BX SNEJF BGB
TOKYO, March 12 (Reuters) - Japan’s Nikkei share average rose over 1 percent on Monday, with technology stocks posting strong gains after February’s U.S. jobs report eased fears of inflation and aggressive interest rate hikes.
PCRFY BRDCF 8035 TOELF TOELY
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET